ACE: A BIOMARKER-BASED APPROACH TO IMPROVING ASTHMA CONTROL

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 哮喘的患病率在世界许多地方都有所增加。 有证据表明，生活在美国内城和经济条件不利的儿童构成了独特和特殊的哮喘风险人群，其特征是发病率和死亡率增加（Akinbami et al，2002; Cloutier et al，2002）。 美国国家过敏和传染病研究所内城哮喘联盟（ICAC）的目标是（1）确定可能促进哮喘控制和预防的免疫疗法形式，（2）设计方案，评估免疫疗法在低收入内城青少年哮喘治疗中的作用，（3）通过与治疗方案平行的机制研究，确定免疫治疗的机制和与低收入城市青少年哮喘发病机制相关的潜在独特机制。 生物标志物在哮喘临床管理中的可用性提供了将该测量应用于对哮喘管理的常规方法仍然难治的特定患者亚群的机会。患有哮喘的城市和内城青少年是一个特别易感的群体，他们的发病率很高。呼出气一氧化氮形式的生物标志物测量的潜在应用为管理和控制哮喘提供了机会，可作为NAEPP指南的辅助手段。 因此，廉政公署进行了一项随机、前瞻性、双盲平行组试验，对象是12至20岁患有持续哮喘的内城青少年。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The prevalence of asthma has increased in many parts of the world. Evidence exists that children living in the inner cities of the United States, and living under economic disadvantages, constitute a unique and special at-risk population for asthma, which is characterized by increased morbidity and morality (Akinbami et al, 2002; Cloutier et al, 2002). The objectives of the National Institutes of Allergy and Infectious Diseases Inner City Asthma Consortium (ICAC) are (1) to identify forms of immune-based therapy that are likely to promote control and prevention of asthma, (2) to design protocols that will evaluate immune-based therapies in the treatment of asthma in low-income inner-city adolescents, and (3) to determine both the mechanisms of immune-based therapies and the potential unique mechanisms associated with the pathogenesis of asthma in low-income inner-city adolescents by the conduct of parallel mechanistic investigations with the therapeutic protocols. The availability of biomarkers in the clinical management of asthma presents presents an opportunity to apply this measurement to a specific subpopulation of patients who remain refractory to the conventional approach to asthma management. The population of urban, inner-city adolescents with asthma is a particularly susceptible group who are subject to a severe degree of morbidity. The potential application of biomarker measurement in the form of exhaled nitric oxide presents an opportunity to manage and control asthma as an adjunct to NAEPP guidelines. The ICAC therefore has conducted a randomized, prospective, double-blind parallel group trial involving inner city adolescents, ages 12-20 years, with persistent asthma.